BCDA BioCardia

BioCardia to Present at the LD Micro 500 Virtual Conference on September 1, 2020

BioCardia to Present at the LD Micro 500 Virtual Conference on September 1, 2020

SAN CARLOS, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) --  [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies today announced that Peter Altman, Ph.D., Biocardia’s Chief Executive Officer will give a virtual corporate presentation at the LD Micro 500 taking place online on Tuesday, September 1, 2020 at 10:20 AM ET followed by a live question and answer session with registered investors and other conference attendees.

Webcast link:

In addition, Dr. Altman will be available for virtual one-on-one meetings beginning on September 1, 2020 and through September 4, 2020.  To schedule a meeting, please contact Eric Lahiji at .

About BioCardia

BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company’s biotherapeutic platforms in clinical development. The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visit .

Media Contact:

Michelle McAdam, Chronic Communications, Inc.



(310) 902-1274

Investor Contact:

David McClung, Chief Financial Officer



(650) 226-0120

EN
26/08/2020

Underlying

BCDABioCardia

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCardia

 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia and CART-Tech Announce Exclusive Partnership to Develop and ...

BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D™ Fusion Imaging for Interventional Cardiology SUNNYVALE, Calif. and UTRECHT, Netherlands, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, and CART-Tech, B.V., a provider of vendor independent platform technology for augmented fluoroscopy during cardiac interventions, today announce that they have entered into an exclusive development and commercialization agreemen...

August 13, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Reports Second Quarter 2025 Business Highlights and Financia...

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results SUNNYVALE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) --  [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2025 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following manageme...

August 11, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia to Host Q2 2025 Corporate Update and Financial Results Confe...

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 SUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended June 30, 2025 by conference call on Monday, August 11, 2025 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for the confere...

August 6, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Provides Update on Timing of Regulatory Activities Seeking F...

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter SUNNYVALE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provides the anticipated timing of regulatory activities seeking FDA and Japan PMDA approvals of its CardiAMP® Cell Therapy System and Helix Transendocardial Delivery Catheter. Q3 2025 He...

August 4, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Submits Request for Clinical Data Review Meeting with Japan ...

BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP® Cell Therapy in Ischemic Heart Failure SUNNYVALE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- [NASDAQ:BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that it submitted its CardiAMP autologous cell therapy investigational heart failure treatment for clinical consultation with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). This milestone marks a significant step toward pote...

July 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch